Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Capricor Therapeutics (CAPR) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to 0.66.

  • Capricor Therapeutics' Equity Ratio fell 968.22% to 0.66 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.66, marking a year-over-year decrease of 968.22%. This contributed to the annual value of 0.85 for FY2024, which is 12173.27% up from last year.
  • Capricor Therapeutics' Equity Ratio amounted to 0.66 in Q3 2025, which was down 968.22% from 0.79 recorded in Q2 2025.
  • Capricor Therapeutics' Equity Ratio's 5-year high stood at 0.85 during Q4 2024, with a 5-year trough of 0.05 in Q3 2023.
  • For the 5-year period, Capricor Therapeutics' Equity Ratio averaged around 0.5, with its median value being 0.38 (2023).
  • As far as peak fluctuations go, Capricor Therapeutics' Equity Ratio tumbled by 11682.08% in 2023, and later skyrocketed by 162631.09% in 2024.
  • Quarter analysis of 5 years shows Capricor Therapeutics' Equity Ratio stood at 0.76 in 2021, then tumbled by 69.0% to 0.24 in 2022, then soared by 63.56% to 0.38 in 2023, then soared by 121.73% to 0.85 in 2024, then dropped by 22.26% to 0.66 in 2025.
  • Its last three reported values are 0.66 in Q3 2025, 0.79 for Q2 2025, and 0.83 during Q1 2025.